- Home
- EDU vs JAZZ Comparison
EDU vs JAZZ Comparison
Compare EDU & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDU | JAZZ |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 10.8B |
| IPO Year | 2006 | 2007 |
Fundamental Metrics
Financial Performance| Metric | EDU | JAZZ |
|---|---|---|
| Price | $52.69 | $170.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $57.87 | ★ $194.40 |
| AVG Volume (30 Days) | 928.6K | ★ 1.6M |
| Earning Date | 01-20-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.27 | N/A |
| Revenue | ★ $4,987,826,000.00 | $4,157,832,999.00 |
| Revenue This Year | $10.59 | $6.00 |
| Revenue Next Year | $10.33 | $6.84 |
| P/E Ratio | $23.23 | ★ N/A |
| Revenue Growth | ★ 7.29 | 4.14 |
| 52 Week Low | $40.66 | $95.49 |
| 52 Week High | $68.53 | $182.99 |
Technical Indicators
Market Signals| Indicator | EDU | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 62.19 |
| Support Level | $50.95 | $164.44 |
| Resistance Level | $54.31 | $182.75 |
| Average True Range (ATR) | 1.16 | 5.88 |
| MACD | 0.02 | -1.21 |
| Stochastic Oscillator | 58.65 | 34.58 |
Price Performance
Historical ComparisonAbout EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.